Immutep IMMP shares are trading higher on Wednesday after the company was granted a European patent for its IMP761.
Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications.
Immutep shares traded up 9.15% to $1.79 on Wednesday at the time of publication. The stock has a 52-week high of $3.10 and a 52-week low of 53 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in